Results shown in Figure 5 illustrate that BAR501 protects against development of signs and symptoms of colitis caused by oxazolone, as shown by assessing the CDAI, the colonic macroscopic features, endoscopy (Figure 5A–E) and colon expression of pro-inflammatory cytokine and Tgf-β (Figure 5F,G), while upregulating the expression of Ace2 by approximately 30% compared to the level of expression measured in mice treated with oxazolone alone (Figure 5H). Here, ACE2 is linked to colitis.